EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer

Laura Boucai

Endocrinology and Metabolism Clinics of North America · 2025

DOI: 10.1016/j.ecl.2025.03.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2025. Verfasst von Laura Boucai. Beteiligte Einrichtung: Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center - Weill Cornell Medical College, 530 East 74th Street, Suite 22…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two-thirds of patients with advanced thyroid cancer are refractory to radioactive iodine (RAI). Inhibition of genetic drivers of thyroid cancer in the intracellular mitogen-activated protein kinase pathway, like BRAF, RAS, RET, and NTRK, results in increased expression of thyroid differentiation genes and the sodium-iodine symporter. Targeted therapies in combination with RAI result in structural decrease of metastatic lesions in 33% to 63% of patients that successfully take up RAI after redifferentiation. The true efficacy of targeted therapies with RAI remains to be proven in clinical trials against the efficacy of targeted therapies without RAI or against multi-kinase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesHumansCell DifferentiationMolecular Targeted Therapy

Stichwörter der Autor:innen

Metastatic thyroid cancerRadio-iodine refractoryRedifferentiation therapiesThyroid cancer

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center - Weill Cornell Medical College, 530 East 74th Street, Suite 22244, New York, NY 10021, USA. Electronic address: boucail@mskcc.org.

Förderung

  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Boucai, L. (2025). An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2025.03.012

Vancouver

Boucai L. An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer. Endocrinology and Metabolism Clinics of North America. 2025. doi:10.1016/j.ecl.2025.03.012

BibTeX
@article{Boucai2025,
  author = {Boucai, Laura},
  title = {An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2025},
  doi = {10.1016/j.ecl.2025.03.012}
}
Kostenlos starten →